Brevan Howard Capital Management LP Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Brevan Howard Capital Management LP boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 626.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,351 shares of the company's stock after purchasing an additional 93,433 shares during the period. Brevan Howard Capital Management LP owned about 0.11% of Intellia Therapeutics worth $1,263,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sterling Capital Management LLC increased its holdings in Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after purchasing an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC bought a new position in Intellia Therapeutics during the fourth quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new stake in Intellia Therapeutics in the fourth quarter worth $43,000. Jones Financial Companies Lllp increased its stake in Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after purchasing an additional 2,280 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Intellia Therapeutics by 80.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock valued at $60,000 after purchasing an additional 2,299 shares during the period. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

NTLA stock traded down $0.41 during trading on Tuesday, hitting $8.14. 1,530,437 shares of the company traded hands, compared to its average volume of 2,478,106. The company has a 50-day moving average of $8.11 and a 200-day moving average of $10.91. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.18. The firm has a market capitalization of $843.17 million, a PE ratio of -1.50 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million for the quarter, compared to analysts' expectations of $11.39 million. The firm's revenue for the quarter was down 42.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.12) EPS. Sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Guggenheim cut their target price on Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating on the stock in a report on Monday. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $13.00 price target (down from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. The Goldman Sachs Group reissued a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Morgan Stanley downgraded Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $56.00 to $11.00 in a research note on Monday, January 27th. Finally, Truist Financial lowered their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $36.90.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.